Get started
Author

Helena Agell

Observed names: Agell, Helena, H. Agell, Helena Agell Gimeno, Helena Agell-Gimeno, Helena  Agell
Institution: Almirall (Spain)
Observed institution: Almirall (Spain)
ORCID: 0009-0005-8742-8062
Observed ORCID: 0009-0005-8742-8062
OpenAlex ID: A5092216025
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
2024 · Eric L. Simpson, Marjolein de Bruin-Weller, et al. · Dermatology and Therapy · 22
PDF
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
2024 · Jonathan I. Silverberg, Andreas Wollenberg, et al. · Dermatology and Therapy · 15
PDF
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials
2024 · Emma Guttman-Yassky, David Rosmarin, et al. · Journal of the American Academy of Dermatology · 12
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
2024 · Eric Simpson, Pablo Fernández-Peñas, et al. · Advances in Therapy · 12
PDF
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)
2025 · Richard B Warren, Marjolein de Bruin-Weller, et al. · British Journal of Dermatology · 8
708 - Raising the bar of efficacy in atopic dermatitis: lebrikizumab maintains depth of response over 2 years
2024 · Eric Simpson, Tilo Biedermann, et al. · British Journal of Dermatology · 5
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis
2025 · Jonathan I Silverberg, Andreas Wollenberg, et al. · Clinical and Experimental Dermatology · 4
Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years From ADjoin
2025 · Emma Guttman-Yassky, Alan Irvine, et al. · SKIN The Journal of Cutaneous Medicine · 3
PDF
626 - Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age
2024 · April Armstrong, Matthew Zirwas, et al. · British Journal of Dermatology · 2
619 - Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)
2024 · Richard B Warren, Marjolein de Bruin-Weller, et al. · British Journal of Dermatology · 2
Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”
2026 · Kim Rand, Kurt Gebauer, et al. · Dermatology and Therapy · 1
PDF
Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)
2026 · Emma Guttman-Yassky, Alan D. Irvine, et al. · Dermatology and Therapy · 1
PDF
Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years
2026 · Eric Simpson, Tilo Biedermann, et al. · Journal of Dermatological Treatment · 1
PDF
Lebrikizumab Improves Anxiety and Depression Symptoms of Adolescents with Moderate-to-Severe Atopic Dermatitis: Results from a 52-Week, Open-label, Phase 3 Study
2025 · Bob Geng, Vinay Mehta, et al. · Journal of Allergy and Clinical Immunology · 1
Achieving Depth of Response in Skin Clearance and Itch Relief With Lebrikizumab is Associated With Minimal Impact of Atopic Dermatitis on Quality of Life
2025 · Raj Chovatiya, Eric Simpson, et al. · SKIN The Journal of Cutaneous Medicine · 1
PDF
Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
2024 · Eric Simpson, Pablo Fernández-Peñas, et al. · Advances in Therapy · 1
PDF
Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year
2023 · Gil Yosipovitch, Claudia Zeidler, et al. · SKIN The Journal of Cutaneous Medicine · 1
PDF
42152 Efficacy of lebrikizumab in patients who did not achieve protocol defined criteria for response after initial 16 weeks of therapy
2023 · Emma Guttman-Yassky, David Rosmarin, et al. · Journal of the American Academy of Dermatology · 1
PDF
Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic Dermatitis
2026 · Linda Stein Gold, Andreas Wollenberg, et al. · Dermatology and Therapy
PDF
Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)
2026 · Emma Guttman-Yassky, Alan D. Irvine, et al. · Dermatology and Therapy
PDF
73841 Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: first year of ADlong Long-Term Extension Trial
2026 · Stephan Weidinger, Alan Irvine, et al. · Journal of the American Academy of Dermatology
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials
2026 · Diamant Thaçi, Luis Puig, et al. · Acta Dermato Venereologica
Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years
2026 · Simpson, Eric, Biedermann, Tilo, et al. · Figshare
Lebrikizumab Improves Anxiety and Depression Symptoms of Adolescents With Moderate-to-Severe Atopic Dermatitis: Results From a 52-Week, Open-label, Phase 3 Study
2026 · Bob Geng, Vinay Mehta, et al. · Journal of Investigative Dermatology
Advancing Atopic Dermatitis Remission Criteria with Lebrikizumab Results in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
2026 · Bob Geng, Mark Boguniewicz, et al. · Journal of Allergy and Clinical Immunology
Works count: 47
Citation count: 93
H-index: 5
I10-index: 4
Year
Topic
Type